Julie Rubinstein Sells 19,060 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,060 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $14.18, for a total value of $270,270.80. Following the sale, the chief operating officer owned 408,160 shares in the company, valued at $5,787,708.80. This trade represents a 4.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total value of $250,639.00.
• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total value of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total value of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total value of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total value of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total value of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total value of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.

Adaptive Biotechnologies Trading Up 2.8%

Shares of Adaptive Biotechnologies stock opened at $14.47 on Friday. Adaptive Biotechnologies Corporation has a twelve month low of $6.77 and a twelve month high of $20.76. The stock has a market capitalization of $2.23 billion, a P/E ratio of -36.17 and a beta of 2.29. The business’s fifty day moving average price is $14.66 and its 200 day moving average price is $15.99.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter last year, the firm earned ($0.23) earnings per share. The firm’s revenue for the quarter was up 51.0% compared to the same quarter last year. As a group, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC raised its position in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP purchased a new position in Adaptive Biotechnologies in the first quarter valued at about $93,000. New York State Common Retirement Fund raised its position in Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in Adaptive Biotechnologies by 728.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on ADPT shares. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Friday, February 6th. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.